Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasm Metastasis 40Lung Neoplasms 32Multiple Myeloma 24Leukemia, Myeloid, Acute 24Colorectal Neoplasms 23Carcinoma, Non-Small-Cell Lung 20Lymphoma 19Breast Neoplasms 19Urinary Bladder Neoplasms 17Pancreatic Neoplasms 16Prostatic Neoplasms 15Ovarian Neoplasms 15Triple Negative Breast Neoplasms 14Melanoma 14Carcinoma, Renal Cell 12Sarcoma 11Glioma 11Carcinoma, Transitional Cell 11Mouth Neoplasms 10Fallopian Tube Neoplasms 10Endometrial Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Neuroblastoma 9Laryngeal Neoplasms 9Glioblastoma 9Carcinoma 9Burkitt Lymphoma 9Stomach Neoplasms 8Oropharyngeal Neoplasms 8Osteosarcoma 7

Interventions

Erlotinib Hydrochloride 2Bevacizumab 2atezolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Contrast Media 1Botulinum Toxins, Type A 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hereditary leiomyomatosis and renal cell cancer × Specimen Handling × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡